# OnCo record paper-archer-1050-lancet-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-archer-1050-lancet-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-archer-1050-lancet-oncol-2017" ;
  schema:name "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial"@en ;
  schema:description "The primary report of ARCHER 1050: dacomitinib held untreated EGFR-mutant lung cancer for a median of 14.7 months against 9.2 months on gefitinib, at the cost of more rash and diarrhoea."@en ;
  schema:url <https://onco.cc/key-papers/paper-archer-1050-lancet-oncol-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30608-3>, <https://pubmed.ncbi.nlm.nih.gov/28958502/>, <https://clinicaltrials.gov/study/NCT01774721> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(17)30608-3> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Wu YL, Cheng Y, Zhou X, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/dacomitinib/>, <https://onco.cc/drugs/gefitinib/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct01774721/> ;
  onco:people <https://onco.cc/people/wu-yi-long/>, <https://onco.cc/people/tony-mok/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .